Saturday, February 11, 2012

Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2011 Financial Results and Recent Developments

March 12, 2011 by  
Filed under class registration

Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2011 Financial Results and Recent Developments
Advancing Three Phase II Programs Targeting Oncology and HCV Infection Indications
Read more on Marketwire

Positive data from Gloucester Pharmaceuticals’ ISTODAX study presented at the ASH meeting

December 6, 2009 by  
Filed under class registration software

Positive data from Gloucester Pharmaceuticals’ ISTODAX study presented at the ASH meeting
Gloucester Pharmaceuticals announced today the presentation of positive data from an analysis of ISTODAX® (romidepsin) in a subset of patients from Gloucester’s registration study in cutaneous T-cell lymphoma (CTCL) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, [...]

Powered by Yahoo! Answers